The debate surrounding GLP-1 receptor agonists (GLP-1 RAs) and their long-term use has been reignited, leaving many questioning the future of these medications. A recent study published in the BMJ has sparked controversy, highlighting the challenges patients face when discontinuing these drugs.
The findings reveal a rapid rebound effect, not only in weight regain but also in the deterioration of cardiometabolic risk markers. This has led to a broader discussion: should these medications be a lifelong commitment for patients?
To unravel this complex issue, we spoke with experts who provided valuable insights.
The Predictable Weight Regain: A Sign of Something Bigger?
Professor Clare Collins, a renowned nutritionist, emphasizes that the rapid weight regain is an expected outcome. However, she highlights the more concerning aspect - the impact on metabolic markers.
"While weight regain attracts attention, it's the deterioration in metabolic health that should worry us the most," Prof Collins states.
Not a Treatment Failure, but a Mechanism at Play
Associate Professor Trevor Steward agrees that the rebound effect is inherent to GLP-1 RAs. These medications amplify existing hormonal signals, particularly those related to appetite and digestion.
"The rapid weight gain upon discontinuation is a result of the body's hormonal balance shifting back to its previous state," explains A/Prof Steward.
But here's where it gets controversial: the mechanisms behind this accelerated rebound are still unclear. Some suggest these medications may cause a stronger rebound effect, almost like a slingshot.
The Missing Piece: Nutrition
Prof Collins' recent systematic review sheds light on a critical aspect often overlooked in incretin trials - dietary intake and nutrition. Most trials focus on weight loss without considering the quality of the diet.
"Reduced intake doesn't guarantee a healthier diet. We must actively monitor nutrition to prevent deficiencies and maintain lean mass," she emphasizes.
Pharmacists, with their frequent patient interactions, can play a vital role in identifying and addressing these issues early on.
Playing the Long Game: Lifelong Treatment?
A/Prof Steward believes that weight regain after cessation is now a well-established phenomenon. Given the risks associated with long-term obesity, continued therapy may be a safer option for some patients.
"For those with a history of weight cycling, GLP-1 RAs are increasingly seen as potential lifelong treatments," he says.
But here's the part most people miss: the importance of clarifying intent and expectations before starting these medications.
"Many people take these drugs for non-health reasons, which is a serious concern. These are powerful medications with whole-body effects, and they should not be taken lightly," A/Prof Steward warns.
Cost and Context: A Balancing Act
Prof Collins believes the BMJ findings shouldn't deter prescribing, but cost considerations are essential, especially with evolving maintenance strategies.
"We must consider the long-term costs and benefits, including potential savings from improved health and reduced medical visits," she suggests.
With new formulations and potential PBS listings, the clinical messaging around GLP-1 RAs will need to adapt.
"Over half a million Australians are now on these medications. We need clearer guidelines on tapering and maintenance to ensure safe and effective use," A/Prof Steward concludes.
For more insights, check out the AP CPD article on weight loss management.
